Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Shares Issued (2020 - 2024)

Relay Therapeutics (RLAY) has disclosed Shares Issued for 5 consecutive years, with $218.2 million as the latest value for Q3 2024.

  • On a quarterly basis, Shares Issued rose 2221.28% to $218.2 million in Q3 2024 year-over-year; TTM through Sep 2024 was $244.3 million, a 16.66% decrease, with the full-year FY2024 number at $17.9 million, down 40.92% from a year prior.
  • Shares Issued was $218.2 million for Q3 2024 at Relay Therapeutics, up from $17.9 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $284.7 million in Q3 2022 to a low of -$2.9 million in Q4 2021.
  • A 5-year average of $35.5 million and a median of $883000.0 in 2022 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: plummeted 5344.64% in 2021, then surged 31463.19% in 2022.
  • Relay Therapeutics' Shares Issued stood at $56000.0 in 2020, then tumbled by 5344.64% to -$2.9 million in 2021, then soared by 59.93% to -$1.2 million in 2022, then skyrocketed by 898.64% to $9.4 million in 2023, then soared by 2221.28% to $218.2 million in 2024.
  • Per Business Quant, the three most recent readings for RLAY's Shares Issued are $218.2 million (Q3 2024), $17.9 million (Q1 2024), and $9.4 million (Q3 2023).